Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model

Cancer Gene Therapy volume 9, pages 330–337 (2002)Cite this article

Abstract

In order to induce specific antitumor immunity in mice, we attempted to immunize C57BL/6 mice with DNA vaccine encoding MUC1 polypeptide. When the mice immunized with MUC1 DNA were challenged with EL4-muc, MUC1-transfected syngeneic lymphoma cells, they completely rejected tumors. When DNA vaccine was given to the EL4-muc tumor-bearing mice, this vaccination was insufficient to suppress tumor growth in the mice. However, activated, but nonprimed dendritic cells (DCs) obtained from syngeneic mice and MUC1 DNA vaccine were given simultaneously to the same site of EL4-muc tumor-bearing mice, tumor growth was markedly suppressed accompanying prolongation of survival time. MUC1 antigen was detected on the DCs at the vaccination site and in regional nodes in the mice which received MUC1 DNA vaccine and DCs. These mice showed markedly enhanced cellular immune responses specific for MUC1 compared to those in mice vaccinated with MUC1 DNA alone. No significant difference in titers of antibodies to MUC1 between the two groups was observed. These results suggest that nonprimed DCs inoculated at the DNA vaccine site are essential for eliciting strong antitumor cellular immunity to suppress tumor growth efficiently in DNA-vaccinated mice. This animal model is useful for developing DNA vaccine for anti-cancer immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Topalian SL, Muul LM, Solomon D et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials J Immunol Methods 1987 102: 127–141

    Article  CAS  PubMed  Google Scholar 

  2. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N Engl J Med 1987 15: 889–897

    Article  Google Scholar 

  3. Pardoll DM . Paracrine cytokine adjuvants in cancer immunotherapy Annu Rev Immunol 1995 13: 399–415

    Article  CAS  PubMed  Google Scholar 

  4. Buchler M, Friess H, Schultheiss KH et al. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer Cancer 1991 68: 1507–1512

    Article  CAS  PubMed  Google Scholar 

  5. Damianov C, Patrashkov T, Tonchev T et al. BCG vaccine therapy for treatment of superficial bladder cancer Int Urol Nephrol 1989 21: 305–312

    Article  CAS  PubMed  Google Scholar 

  6. Clemens JD, Stanton BF . BCG prophylaxis against cancer: methodological evaluation of a continuing controversy J Chronic Dis 1984 37: 45–54

    Article  CAS  PubMed  Google Scholar 

  7. Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial Lancet 1999 353: 345–350

    Article  CAS  PubMed  Google Scholar 

  8. Hoover HC, Hoover HC Jr, Brandhorst JS et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase II prospectively randomized trial J Clin Oncol 1993 11: 390–399

    Article  PubMed  Google Scholar 

  9. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunogenic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 1998 4: 321–327

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Marchand M, Weynants P, Rankin E et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 Int J Cancer 1995 63: 883–885

    Article  CAS  PubMed  Google Scholar 

  11. Donnelly JJ, Ulmer JB, Liu MA . DNA vaccine Life Sci 1997 60: 163–172

    Article  CAS  PubMed  Google Scholar 

  12. Maecker HT, Uematsu DT, DeKruyff RH et al. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC J Immunol 1998 161: 6532–6536

    CAS  PubMed  Google Scholar 

  13. Klimman DM, Sechler JMG, Conover J et al. Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory J Immunol 1998 160: 2388–2392

    Google Scholar 

  14. Iwasaki A, Barber BH . Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope–expressing tumor Cancer Immunol Immunother 1998 45: 273–279

    Article  CAS  PubMed  Google Scholar 

  15. Chen Y, Hu D, Eling DJ et al. DNA vaccine encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors Cancer Res 1998 58: 1965–1971

    CAS  PubMed  Google Scholar 

  16. Chen CH, Wang TL, Hung CF et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene Cancer Res 2000 60: 1035–1042

    CAS  PubMed  Google Scholar 

  17. Graham RA, Burchell JM, Beverley P et al. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells Int J Cancer 1996 65: 664–670

    Article  CAS  PubMed  Google Scholar 

  18. Mendirata SK, Thai G, Eslahi NK et al. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2 Cancer Res 2001 61: 859–863

    Google Scholar 

  19. Seregni E, Botti C, Lombordo C et al. Pattern of mucin expression in normal and neoplastic lung tissues Anticancer Res 1996 16: 2209–2214

    CAS  PubMed  Google Scholar 

  20. Ho SB, Shekels LL, Toribara NW et al. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium Cancer Res 1995 55: 2681–2690

    CAS  PubMed  Google Scholar 

  21. Ogata S, Uehara H, Chen A et al. Mucin gene expression in colonic tissues and cell lines Cancer Res 1992 52: 5971–5978

    CAS  PubMed  Google Scholar 

  22. Lan ML, Hollingsworth MA, Metzgar RA . Polypeptide coreofa human pancreatic tumor antigen Cancer Res 1990 50: 2997–3001

    CAS  PubMed  Google Scholar 

  23. Apostolopoulos V, Haurum JS, McKenzie IF . MUC1 peptide epitopes associated with five different H-2 class I molecules Eur J Immunol 1997 27: 2579–2587

    Article  CAS  PubMed  Google Scholar 

  24. Barnd DL, Lan M, Metzgar R et al. Specific, MHC-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells Pro Natl Acad Sci USA 1989 86: 7159–7163

    Article  CAS  Google Scholar 

  25. Itoh Y, Kajino K, Ogasawara K et al. Determination of the allele-specific antigen-binding site on I-Ak and I-Ab molecules Eur J Immunol 1996 26: 1314–1321

    Article  CAS  PubMed  Google Scholar 

  26. Leitner WW, Ying H, Driver DA et al. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors Cancer Res 2000 60: 51–55

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Burchell J, Gendler S, Taylor-Papadimitriou J et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the protein core of the human milk mucin Cancer Res 1987 47: 5476–5482

    CAS  PubMed  Google Scholar 

  28. Finn OJ, Barnd DL, Kerr L et al. Specific recognition of human tumor antigens by non–MHC-restricted CTL Human Tumor Antigens and Specific Tumor Therapy New York, USA: Alan R Liss 1989

    Google Scholar 

  29. Apostolopoulos V, Karanikas V, Haurum JS et al. Induction of HLA-A2–restricted CTLs to the mucin 1 human breast cancer antigen J Immunol 1997 159: 5211–5218

    CAS  PubMed  Google Scholar 

  30. Karanikas V, Hwang LA, Pearson J et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan–MUC1 fusion protein J Clin Invest 1997 100: 2783–2792

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Domenech N, Henderson RA, Finn OJ . Identification of an HLA-A11–restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin J Immunol 1995 155: 4766–4774

    CAS  PubMed  Google Scholar 

  32. Bot A, Stan AC, Inaba K et al. Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class I–restricted cytolytic lymphocytes upon adoptive transfer Int Immunol 2000 12: 825–832

    Article  CAS  PubMed  Google Scholar 

  33. Zarling AL, Johnson JG, Hoffman RW et al. Induction of primary human CD8+ T lymphocyte responses in vitro using dendritic cells J Immunol 1999 162: 5197–5204

    CAS  PubMed  Google Scholar 

  34. Kontani K, Taguchi O, Narita T et al. Autologous dendritic cells or cells expressing both B7-1 and MUC1 can rescue tumor-specific cytotoxic T lymphocytes from MUC1-mediated apoptotic cell death J Leukocyte Biol 2000 68: 225–232

    CAS  PubMed  Google Scholar 

  35. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate–pulsed dendritic cells Nat Med 1998 4: 328–332

    Article  CAS  PubMed  Google Scholar 

  36. Lohmann S, Galle K, Knop J et al. CD83+ human dendritic cells transfected with tumor peptide cDNA by electroporation induce specific T-cell responses: a potential tool for gene immunotherapy Cancer Gene Ther 2000 7: 605–614

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported, in part, by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan (08671356, 10671249, and 13671380).

Author information

Authors and Affiliations

  1. Second Department of Surgery, Shiga University of Medical Science, Otsu, 520-2192, Japan

    Keiichi Kontani, Yoshitomo Ozaki, Jun Hanaoka, Noriaki Tezuka, Satoru Sawai, Shuhei Inoue & Shozo Fujino

  2. Laboratory of Experimental Pathology, Aichi Cancer Center Research Institute, Nagoya, 464-8681, Japan

    Osamu Taguchi

  3. Department of Medical Biochemistry, Shiga University of Medical Science, Otsu, 520-2192, Japan

    Toshinaga Maeda & Iwao Ohkubo

  4. Department of Pathology, Shiga University of Medical Science, Otsu, 520-2192, Japan

    Yasushi Itoh & Kazumasa Ogasawara

  5. Department of Biology, Shiga University of Medical Science, Otsu, 520-2192, Japan

    Hiroshi Sato

  6. Institute of Department, Cell Resource Center for Biochemical Research, Aging and Cancer, Tohoku University, Sendai, 980-8575, Japan

    Toshio Kudo

Authors
  1. Keiichi Kontani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Osamu Taguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshitomo Ozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Hanaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Noriaki Tezuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Satoru Sawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shuhei Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shozo Fujino
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toshinaga Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasushi Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kazumasa Ogasawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroshi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Iwao Ohkubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Toshio Kudo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keiichi Kontani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kontani, K., Taguchi, O., Ozaki, Y. et al. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model. Cancer Gene Ther 9, 330–337 (2002). https://doi.org/10.1038/sj.cgt.7700444

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700444

Keywords

This article is cited by

Search

Advanced search

Quick links